NFL BIOSCIENCES: Decision to grant patent in China

NFL BIOSCIENCES: Decisionhave understood Of rescue his Patent In China

NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), A biopharmaceutical company developing botanical drugs for addiction and the treatment of addiction, publication With the consent of the Chinese Nationwide intellectual property Management (CNIPA), for delivery his Patent (China application number201780033409.5) Wearing upon NFL-101, Nicotine-free, a botanical drug candidate composed of natural proteins extracted from tobacco leaves When mainly Destiny no smoking.. This patent protectsra MeThe innovation behind the NFL-101 Until then 2036 In China..

NFL Biosciences has adopted a knowledge management and protection strategy and has filed two patent families to grant exclusive rights to the candidate drug NFL-101. This product patent was originally filed and approved in France and relates to “an aqueous extract of tobacco leaves and its use in the treatment of addiction”. Therefore, the underlying innovations of the NFL-101 will be protected in France, the United States, and thus soon in China until 2036. Domestic registration applications are also under review in Japan, Canada, South Korea, Australia, Brazil, India, Indonesia, Israel, Mexico, Philippines, Eurasia, Saudi Arabia, United Arab Emirates and Nigeria.

China has the highest number of smokers, exceeding 300 million, and about 50% of the male population is smokers. If nothing is done, smoking-related cancer deaths are expected to increase by 44% among men between 2020 and 2040, which represents the mortality displacement of 8.6 million deaths in 20 years. ..1.. Smoking reduction is a national issue and is at the heart of the Healthy China initiative, which aims to improve the health of the Chinese people, especially to reduce overall smoking rates to 20% in 2030. It is integrated.

“” Nearly one-third of the cigarettes smoked in the world are smoked in China. When you get a product patent, a protection Strong to develop strategy in the next few years.. This patent Strengthen protection Innovation on that Our drug candidate NFL-101 In China, Countries that are part of the market Key GoalStars global approach Deployed by NFL Bioscience. He is so It is important for us to have solid intellectual property in this high potential market Bruno Lafont, Deputy CEO and Co-Founder of NFL Biosciences, said.

About NFL Bioscience

NFL Biosciences is a biopharmacy company based in the Montpellier region, developing botanical drug candidates for the treatment of addiction. NFL Biosciences aims to provide new therapeutic, natural, safe and effective solutions to people around the world, not forgetting low-income or middle-income countries. Its most advanced product, called NFL-101, is a standardized nicotine-free tobacco leaf extract protected by two patent families. NFL Biosciences is intended to provide smokers who want to quit their natural, safe, simplified and personalized management options. NFL Biosciences is also developing NFL-301, a natural drug candidate for reducing alcohol consumption, and has a drug development project for the treatment of cannabis use disorders.

The shares of NFL Biosciences are listed on Euronext Growth Paris (FR0014003XT0 – ALNFL). The company qualifies as an “innovative company” for FCPI investment. More information at www.nflbiosciences.com

contact address

Bruno Lafon – [email protected] – 04 11 93 76 67 Calyptus Agency – [email protected] – 01 53 65 68 68


1 inchSmoking-related cancer deaths in men and women in an aging society (China 2020–2040): Population-based modeling studies2021 September 1: https: //tobaccocontrol.bmj.com/content/early/2021/09/01/tobaccocontrol-2020-056444

  • 20220411_NFLBioscience_brevet_Chine_FR_DEF


Easy to print, PDF and email